Safety and Efficacy of Intracameral Zimoxin for Prevention of Endophthalmitis After Cataract Surgery
| Status: | Not yet recruiting |
|---|---|
| Conditions: | Ocular, Ocular |
| Therapuetic Areas: | Ophthalmology |
| Healthy: | No |
| Age Range: | 40 - Any |
| Updated: | 6/28/2018 |
| Start Date: | October 1, 2018 |
| End Date: | October 2019 |
| Contact: | Jason Ahee, M.D. |
| Email: | aheejason@hotmail.com |
| Phone: | 435-216-7676 |
Safety and Efficacy of Intracameral Zimoxin (0.1% Moxifloxacin Solution) for Prevention of Endophthalmitis After Cataract Surgery
Intracameral injection of 0.1% moxifloxacin solution after cataract surgery to prevent
endophthalmitis
endophthalmitis
Subjects will receive either intracameral injection of 0.1% moxifloxacin solution or placebo
after cataract surgery. They will be followed for one month to determine if there is a
statistically significant difference in the incidence of endophthalmitis.
after cataract surgery. They will be followed for one month to determine if there is a
statistically significant difference in the incidence of endophthalmitis.
Inclusion Criteria:
- visually significant cataracts
Exclusion Criteria:
- allergy to fluoroquinolones
We found this trial at
1
site
Click here to add this to my saved trials
